The National Institute for Health and Clinical Excellence has issued technology appraisal guidance on the use of paclitaxel for ovarian cancer (updated in January 2003) and on the use of topotecan, pegylated liposomal doxorubicin hydrochloride (PLDH) and paclitaxel for the treatment of advanced ovarian cancer (May 2005).